Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 577

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 577
---
,346 shares of Kineta Common Stockand received net proceeds of $7.4 million. The second closing of the Private Placement for an aggregate purchase price of $22.5 million was expected to occur on April 15, 2024, however, the investors failed to fulfill their contractual obligation to fund and the second closing did not occur. Kineta has reached a settlement with one investor and have initiated litigation against the other investors which failed to fund their obligations.**

<div align='center'>372</div>

Geopolitical Developments Geopolitical developments, such as the Russian invasion of Ukraine, the conflict in Israel and the Gaza Strip or deterioration in the bilateral relationship between the United States and China, may impact government spending, international trade and market stability, and cause weaker macro-economic conditions. The impact of these developments, including any resulting sanctions, export controls or other restrictive actions that may be imposed against governmental or other entities in, for example, Russia, have in the past contributed and may in the future contribute to disruption, instability and volatility in the global markets, which in turn could adversely impact Kineta’s operations and weaken Kineta’s financial results. Certain political developments may also lead to uncertainty to regulations and rules that may materially affect Kineta’s business. Nasdaq Suspension and Delisting As previously disclosed in a Current Report on Form 8-Kfiled on September 10, 2024, Kineta received a determination letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC informing Kineta that after reviewing the materials submitted by Kineta, the Staff had determined to deny Kineta’s request for continued listing on The Nasdaq Capital Market due to Kineta’s lack of compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). In the Letter, the Staff also notified Kineta that trading of its securities would be suspended and the securities would be removed from listing and registration on Nasdaq unless Kineta requested an appeal of Nasdaq’s determination by September 17, 2024. Kineta did not appeal the determination, and therefore, Kineta Common Stock was suspended from trading on The Nasdaq Capital Market at the opening of business on September 19, 2024. Since September 19, 2024, Kineta Common Stock has been trading on the OTC Pink Market under the symbol “KANT.” Effective as of October 25, 2024, Kineta Common Stock was delisted